Skip to content
Try Mental Wellness – Lifestyle
Author:
Sunshine Biopharma Inc.
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
May 29, 2026
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
May 28, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
May 21, 2026
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
May 19, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
May 18, 2026
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
April 6, 2026